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Summary Medulloblastoma is the most frequent paediatric brain tumour. Because of the uniform histology, a common genetic mechanism
has been postulated. Loss of heterozygosity (LOH) studies support evidence that a candidate gene, which functions as a tumour-suppressor
gene, is located in 17p13. Eighteen tumours were examined for loss of heterozygosity at 15 different loci at chromosome 17p. Nine of 18
(50%) tumours had allelic loss in 17p 13.3-13.2. The smallest region of overlap, which harbours the disease gene, includes markers from
UT222 (Dl7S675) to UT49 (Dl7S731) and spans a region of less than 6 cM. Candidate genes within this region are HIC-1, a potential
tumour-suppressor gene, and DPH2L, a gene that has been cloned from the ovarian critical region. The putative region excludes the p53
gene and the ABR gene, which have been favoured by others. LOH of chromosome 17p may be used as a new prognostic biological marker.
Children with an allelic loss had a poorer prognosis than those patients without loss of heterozygosity (P<0.05).
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Medulloblastoma is the most common malignant brain tumour in
children. Although little is known about the aetiology of this
tumour, the short arm of chromosome 17 is most often involved.
Cytogenetic and molecular rearrangements, in particular isochro-
mosome 17q, have been reported in 30-50% ofcases (Bigner etal,
1988; Biegel et al, 1989). Although there is no familial occurrence
ofmedulloblastoma, the uniform histology and rare occurrence of
subtypes of this primitive neuroectodermal tumour (PNET)
suggest a common genetic mechanism.
Solid tumours often unmask a genetic alteration in a single
tumour-suppressor gene by an allelic loss during tumour progres-
sion. Loss of heterozygosity and deletion mapping of chromo-
somal regions of interest is a powerful method to locate specific
tumour-suppressor genes and to discover cancer genes by posi-
tional cloning. Highly polymorphic microsatellite markers have
been proven to be an important tool for LOH studies.
There are several lines of evidence that a locus resides within
the most terminal region of the chromosome in 17pl3.3, which
seems to be essential in the development and/or progression of
medulloblastoma (Biegel et al, 1992). Cogen et al (1990) found
recurrent allele losses within this band, and Chen et al (1994)
reported functional evidence of a tumour-suppressor gene other
than p53 on 17p. The ABR gene, which is expressed in brain, has
been favoured as a candidate. However, specific mutations have
not yet been found (Cogen et al, 1992). The race for a specific
medulloblastoma gene has not come to an end.
In the search forthe smallest region ofoverlap, we constructed a
deletion map in a panel of 18 tumours. The order ofmarkers relied
on extended genetic linkage studies and have been constructed by
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several groups (White et al, 1985; Wright et al, 1990; O'Connell et
al, 1993; Gerken et al, 1995).
The aim of the study was to narrow down the interval and to
provide mapping information for the subsequent search for the
putative tumour-suppressor gene. In addition, we related the
molecular results to clinical outcome to search for an additional
biological prognostic factor.
MATERIAL AND METHODS
Eighteen blood-tumour pairs from children operated upon for
medulloblastoma were collected. The histology was confirmed by
two reference centres. None of the patients was exposed to radia-
tion or chemotherapy before surgery. Age at diagnosis ranged
from 3 to 17 years. One patient was below 3 years and five patients
were below 5 years at diagnosis.
Tumour DNA was extracted from paraffin-embedded pathology
material except in four cases, for which frozen material was avail-
able. This DNA was extracted using the Quiagen tissue kit. The 18
markers used were published by Gerken et al (1995) and are as
follows: UT18 (D17S643), UT20 (D17S654), UT158 (D17S619),
UT39 (D17S720), UT225 (D17S678), UT222 (D17S675),
UT5265 (D17S1149) UT751 (D17S906), UT184 (D17S647),
UT49 (D17S731), UT1985 (D17S919), UT72 (D17S755), UT403
(D17S1148), UT405 (D17S900), UT263 (D17S689). We further
tested two additional tumour-suppressor genes on other chromo-
somes APC (5q21) and DCC (18q21.3). The primer sequences are
found in the relevant references (Gerken et al, 1994; Boland et al,
1995) and GenBank. For polymerase chain reaction (PCR) ampli-
fication, one of each marker was end labelled with [y-32P]ATP
(3000 Ci mmol- , Amersham) and T4 DNA polynucleotide kinase.
(Bohringer-Mannheim). PCR products were electrophoresed
through denaturing 6% gels and exposed to radiographic film for
4-72 h (Figure 1). A standard PCR cycle consisted of a single
denaturing step at 3 min, followed by 30 cycles at 94°C for 45 s,
55-63'C for 45 s and 72°C for 45 s. A final extension step was
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Figure 1 Example of detection of loss of heterozygosity. LOH was analysed
by comparing normal (blood) DNA (N) with tumour DNA (T). Patients m-11
and m-8 demonstrate LOH with marker UT5265 and UT49 respectively;
patient m-12 retained both alleles in the tumour
added at 72°C for 5 min. The annealing temperature and Mg++
concentrations were previously tested for each primer pair.
The statistical analysis for Kaplan-Meier plot was performed
with the program SPSS for windows 7.0.
RESULTS
Eighteen blood-tumour pairs have been tested for loss of
heterozygosity at 15 17p loci and for allelic loss at two tumour-
suppressor genes: APC at 5q21 and DCC at 18q21.3. The DNA
markers covered an interval of45 cM. Loss ofheterozygosity was
found in 9 of 18 samples (50%). The majority of the patients
showed long-range losses extending over a large chromosomal
region on 17p. Those deletions correspond well with the cyto-
genetically reported data of isochromosome 17q. In our set of
tumours, they were present in 5 of 18 samples (27%). Two
patients (m- 11 and m-16) had a deletion that was clearly defined
as interstitial, but still the interval was not limited to one or two
markers (Figure 2). In a second screen, we introduced closely
linked markers within the putative region of the tumour-
suppressor gene. However, going back to all previously negative
tumour samples, we did not find hitherto undiscovered micro-
deletions. Taking all deletions together, the smallest interval of
overlap spans a region ofabout 6 cM including UT 751. Flanking
markers at the telomeric site are UT 5265 and at the centromeric
site UT 1985. This region has been assigned to the chromosomal
band 17pl3.3-13.2.
TP53 is included in some long distance deletions but is not
contained by the two interstitial deletions and is localized down-
stream from UT 751 in 17pl3.1. In order to check if allelic loss in
chromosome 17 was specific, we tested other known tumour-
suppressor genes: APC on 5q21 and DCC on chromosome
18q21.3. All tumours except one (m-13) retained those genes. The
m-13 tumour was taken from metastasis, and this may explain this
additional and probably unspecific loss as part of the multistep
process of carcinogenesis. Sequences at the DCC locus were
retained in all tumours.
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Figure 2 PCR analysis of 18 medulloblastoma tumour specimens using 15 microsatellites on chromosome 17p. The results of the analysis for those tumours
displaying 17p deletions are summarized. The order of the microsatellites follows previously published sequences in GenBank and in *Gerken et al (1995)
British Journal ofCancer (1997) 76(10), 1284-1287
Position
pl
m-s
Am
m-16 Composite
Af "
^ e!
_
0CancerResearch Campaign 19971286 E Steichen-Gersdorfet al
1.0-
0.9-
76 0.8-
cn 0.7_
Cu
.0 co
0
XL 0.5_
0.4-
0.3-
I._ L P<0.05
L1n
n=9
L--
L --- n=9
I I I I F TI I I I
0 1 2 3 4 5 6 7 8 9 10
Survival (years)
Figure 3 Kaplan-Meier survival curve based on 17p deletion. In the group
of patients whose tumours retained 17p two patients died, compared with six
patients within the group of patients who lost heterozygosity. No 17p
deletion; ---, 17p deletion
Patients' survival data were analysed using a Kaplan-Meier plot
(Figure 3). The observation time was more than 3 years except in
two patients, in whom thefollow-up period was 1 year. We found a
statistically significant correlation of LOH at 17p with poorer
outcome. The number of patients was too small to split up the
patient groups by including more clinical data.
DISCUSSION
Loss ofheterozygosity on chromosome 17p has been found to be a
frequent and specific event in medulloblastoma. We confirmed this
result by testing 18 patients for allelic losses in tumours compared
with constitutional DNA. As a result, we found LOH in 9 of 18
(50%) patients.
Most tumours showed long-range allele losses with interspersed
stretches without allele loss. This pattern of discontinuous distrib-
ution has also been described by other authors. This might be
because of a problem of the physical order of markers, which is
still preliminary, or more likely it is a real phenomenon and the
consequence of recurrent rearrangement in the progression of the
tumour itself. Non-continuous deletion could also be explained
with homozygous deletion and a contaminating normal allele
appearing to show retention. As we observed no contamination
by normal connective tissue in heterozygous allele losses, even
after very long exposures, we do not think that this explanation is
relevant in the case of medulloblastoma. In case m-14, marker
D17S755 was retained, whereas flanking markers were lost. This
also argues against contamination.
Two samples however showed a clearly interstitial pattern.
Those deletions had a major impact on the composite map of all
deletions. The distal breakpoint was located between UT225 and
UT222 in tumour m-16. Tumour m-14 located the distal end below
UT222, which also located the putative gene below this marker.
The proximal breakpoint in m-16 was localized in UT 72; the
proximal breakpoint of tumour m-6 mapped above this marker in
UT 1985, which placed the gene above this marker. The composite
map localized an interval, extending from UT 222 (D17S675) to
UT 49 (D17S731). All those markers have been assigned to the
chromosomal band 17pl3.3-13.2.
The genetic distance ofthis interval is considered to be less than
6 cM. In terms of physical distance, the size is not known exactly
but may be as big as 6 Mb. However, as the 1 cM/1 megabase rule
does not always apply, especially close to the telomere, the region
could be as small as 2 Mb. Although we were able to narrow-down
the interval, the region of interest still seems to be too big to be
easily cloned. Deletion mapping in tumours, however, provides
good information to aid in the search for candidate genes that have
been cloned and mapped within this interval. The minimum region
of allelic loss in 17pl3.3 allows us to consider several candidate
genes and to exclude some others. Tumour-suppressor genes for
various types of cancer have been located at the short arm ofchro-
mosome 17p. Some ofthem have also been discussed in relation to
ovarian cancer, which does not show any relationship to PNETs and
does not occur with a higher incidence in relatives of a patient
with medulloblastoma. ABR (active BCR-related gene) has been
favoured as a strong candidate because it is specifically expressed
in brain. Mutations however have not yet been found (McDonald et
al, 1994). According to our results, this gene maps outside the
region ofinterest. Ithas been mapped in close relation to the VNTR
probe pl44-D6, which was lost in only two tumours in our study.
TP53, which is involved in the course ofmany different tumours,
has already been excluded as a strong candidate and is infrequently
altered in relapses or after chemotherapy (Saylors et al, 1991).
HIC-l (hypermethylated in cancer) must be included as a candi-
date. It encodes a zinc-finger transcription factor and is expressed
ubiquitously in normal tissue. Koch et al (1996) (abstract
presented at the European Association for Neuro-Oncology
meeting) investigated HIC-1 in eight medulloblastoma cell lines;
mRNA was not detectable in all, which is rather suspicious. The
authors concluded that HIC-1 may contribute to the pathogenesis
ofmedulloblastoma, but as yet there is no proof.
Recently characterized genes within this region are OVCA1
(DPH2L) and OVCA2, cloned from the ovarian cancer critical
region of deletion in chromosome 17pl3.3. Two distinct
transcripts of approximately 2.3 and 1.1 kb are ubiquitously
expressed; their protein is highly conserved (Schultz et al, 1996).
OVCA1 has 13 exons and spans approximately 20 kb of genomic
DNA. Mutational analysis has been advised, but mutations have
not yet been published.
AGK2 is a new microsatellite marker that has been detected
through the cloning ofthe OVCA genes. This marker was deleted in
5 of 18 tumours tested; three tumours were not informative. The
deletion pattern of AGK2 in five patients, all with LOH 17p, led us
to locate this markerand the OVCA genes within the smallestregion
ofoverlap described, and argues for the OVCA genes as being good
candidates. All tumours were informative for D17S796 (UT751),
and nine of nine samples (100%) were deleted at this locus. Genes
within this locus are strong candidates for the putative medulloblas-
toma gene. There is other evidence that favours this region. Zajac et
al (1997) located the 17p breakpoint of a sporadic X/17 transloca-
tion in a young girl with aplexupapilloma nearUT 751. This patient
has been reported previously (Steichen et al, 1993). Although this
tumour is different to medulloblastoma, there may have been a
common mechanism of tumour predisposition. The junction frag-
ment was cloned. Transcribed sequences from two cosmids included
FXR2, a mental retardation gene and SHBG (sex hormone binding
globulin), but no gene rearrangement was found. It is most likely
that those genes are not real candidates, but they still fall within the
interval. A positional effect with a putative tumour-suppressor gene
must be considered.
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We also tested LOH of chromosome 17p markers for its
prognostic significance. Conventional prognosis defines poor risk
factors, such as age <3 years, residual tumour after surgery and
metastatic spread (Packer et al, 1989). Statistical analysis using the
Kaplan-Meier plot showed a significantly worse prognosis for
patients with a 17p deletion (P < 0.05). These data are in accordance
with Batra et al (1995) and may evaluate this genetic test as a new
prognostic marker (Figure 3). Having narrowed down the region to
an interval of < 6 cM by analysing 18 tumours for loss ofheterozy-
gosity, we are currently looking for mutations in candidate genes.
This study together with previous investigations justify the
construction of a physical map for positional cloning of a putative
tumour-suppressor gene in 17p13.
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